Dbv Technologies SA's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 88 out of 155 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 41.00.In the medium term, the stock price is expected to remain stable.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Media Coverage
The current financial score of Dbv Technologies SA is 7.43, ranking 106 out of 155 in the Pharmaceuticals industry. Its financial status is robust, and its operating efficiency is low. Its latest quarterly revenue reached 900.00K, representing a year-over-year increase of 19.52%, while its net profit experienced a year-over-year increase of 75.78%.
Key Metrics
The current valuation score of Dbv Technologies SA is 6.51, ranking 119 out of 155 in the Pharmaceuticals industry. Its current P/E ratio is -4.37, which is -49.36% below the recent high of -2.21 and -340.74% above the recent low of -19.24.
The current earnings forecast score of Dbv Technologies SA is 7.67, ranking 97 out of 155 in the Pharmaceuticals industry. The average price target is 20.00, with a high of 35.00 and a low of 7.94.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
The current price momentum score of Dbv Technologies SA is 6.73, ranking 84 out of 155 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 21.07 and the support level at 18.57, making it suitable for range-bound swing trading.
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
The current institutional shareholding score of Dbv Technologies SA is 3.00, ranking 94 out of 155 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 5.92%, representing a quarter-over-quarter increase of 26.42%. The largest institutional shareholder is Steven Cohen, holding a total of 0.00 shares, representing 0.00% of shares outstanding, with 1.00% increase in holdings.
The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Dbv Technologies SA is 2.46, ranking 124 out of 155 in the Pharmaceuticals industry. The company's beta value is -0.98. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.
